Please help us continue to improve nanoHUB operation and service by completing our survey - http://bit.ly/nH-survey14. Thank you - we appreciate your time. close

Support

Support Options

Submit a Support Ticket

 

BME 695N Lecture 4: Designing "Theragnostic" Systems

By James Leary

Purdue University

Published on

Abstract

Outline:
  1. Bridging the gap between diagnostics and therapeutics
    1. How conventional medicine is practiced in terms of diagnostics and therapeutics
    2. The consequences of separating diagnostics and therapeutics
    3. A new approach – "theragnostics" (or "theranostics")
  2. Examples of current theragnostic systems
    1. Example: Rituxan ("Rituximab)(an example of not using diagnostics to guide the therapy)
    2. Example 1: Herceptin ("terastuzumab")
    3. Example 2: Iressa ("Gefitinib)
  3. How theragnostics relates to Molecular Imaging
    1. Conventional imaging is not very specific
    2. Types of In-vivo Imaging
      1. X-rays, CAT (Computed Axial Tomography) scans
      2. MRI (magnetic Resonance Imaging)
      3. PET (Positron Emission Tomography) scans
    3. "Molecular Imaging"
  4. Engineering nanomedical systems for simultaneous molecular imaging
    1. Using nanomedical cores for MRI contrast agents
    2. Difficulties in using PET probes for nanomedical devices
    3. Using cell-specific probes for molecular imaging of nanomedical devices
    4. Breaking the "diffraction limit" – nano-level imaging
  5. Theragnostic nanomedical devices
    1. Using nanomedical devices to guide separate therapeutic device
    2. When might we want to combine diagnostics and therapeutics?

References

Cite this work

Researchers should cite this work as follows:

  • James Leary (2007), "BME 695N Lecture 4: Designing "Theragnostic" Systems," http://nanohub.org/resources/3109.

    BibTex | EndNote

Time

Location

Biomedical Engineering Building, Rm 1083

Tags

nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.